Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
Ruella M, Filippi AR, Bruna R, Di Russo A, Magni M, Caracciolo D, Passera R, Matteucci P, Di Nicola M, Corradini P, Parvis G, Gini G, Olivieri A, Ladetto M, Ricardi U, Tarella C, Devizzi L. Ruella M, et al. Among authors: caracciolo d. Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):783-91. doi: 10.1016/j.ijrobp.2015.12.019. Epub 2015 Dec 17. Int J Radiat Oncol Biol Phys. 2016. PMID: 26972651
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma.
Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V, Corradini P, Carobbio A, Mulé A, Bosa M, Barbui A, Di Nicola M, Sorio M, Caracciolo D, Gianni AM, Rambaldi A. Tarella C, et al. Among authors: caracciolo d. J Clin Oncol. 2011 Mar 1;29(7):814-24. doi: 10.1200/JCO.2010.28.9777. Epub 2010 Dec 28. J Clin Oncol. 2011. PMID: 21189387
Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma.
Ferrero S, Monitillo L, Mantoan B, Barbero D, Genuardi E, Barbiero S, Bernocco E, Caracciolo D, Ruella M, Drandi D, Zanni M, Renna F, Lobetti Bodoni C, Gueli A, Passera R, Musto P, Boccadoro M, Tarella C, Ladetto M. Ferrero S, et al. Among authors: caracciolo d. Ann Hematol. 2013 Nov;92(11):1503-11. doi: 10.1007/s00277-013-1797-y. Epub 2013 Jun 5. Ann Hematol. 2013. PMID: 23737092
Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy.
Filippi AR, Piva C, Giunta F, Bellò M, Chiappella A, Caracciolo D, Zotta M, Douroukas A, Ragona R, Vitolo U, Bisi G, Ricardi U. Filippi AR, et al. Among authors: caracciolo d. Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):311-6. doi: 10.1016/j.ijrobp.2013.05.053. Epub 2013 Aug 2. Int J Radiat Oncol Biol Phys. 2013. PMID: 23916170 Free article.
Prognostic Role of Pre-Radiation Therapy (18)F-Fluorodeoxyglucose Positron Emission Tomography for Primary Mediastinal B-Cell Lymphomas Treated with R-CHOP or R-CHOP-Like Chemotherapy Plus Radiation.
Filippi AR, Piva C, Levis M, Chiappella A, Caracciolo D, Bellò M, Bisi G, Vitolo U, Ricardi U. Filippi AR, et al. Among authors: caracciolo d. Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1239-43. doi: 10.1016/j.ijrobp.2016.02.057. Epub 2016 Mar 2. Int J Radiat Oncol Biol Phys. 2016. PMID: 27130796
The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.
Rambaldi A, Boschini C, Gritti G, Delaini F, Oldani E, Rossi A, Barbui AM, Caracciolo D, Ladetto M, Gueli A, De Crescenzo A, Passera R, Devizzi L, Patti C, Gianni AM, Tarella C. Rambaldi A, et al. Among authors: caracciolo d. Am J Hematol. 2013 Dec;88(12):1062-7. doi: 10.1002/ajh.23566. Epub 2013 Sep 30. Am J Hematol. 2013. PMID: 23940056 Free article.
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).
Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, Zoli V, Fornari A, Novero D, Cabras A, Stella M, Comino A, Remotti D, Ponzoni M, Caracciolo D, Ladetto M, Magni M, Devizzi L, Rosato R, Boccadoro M, Bregni M, Corradini P, Gallamini A, Majolino I, Mirto S, Gianni AM; Gruppo Italiano Terapie Innovative nei Linfomi. Tarella C, et al. Among authors: caracciolo d. Leukemia. 2007 Aug;21(8):1802-11. doi: 10.1038/sj.leu.2404781. Epub 2007 Jun 7. Leukemia. 2007. PMID: 17554382
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage.
Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota Scalabrini D, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL). Ladetto M, et al. Blood. 2008 Apr 15;111(8):4004-13. doi: 10.1182/blood-2007-10-116749. Epub 2008 Jan 31. Blood. 2008. PMID: 18239086 Free article. Clinical Trial.
124 results